St. Jude Medical Inc. envisions both immediate and future product development opportunities as a result of its Aug. 19 acquisition of Endosense SA, a Swiss developer of technology that senses the contact force between an ablation catheter and the target tissue.
St. Jude paid $170 million in cash for privately held Endosense, with an additional milestone payment of up to $161 million contingent upon the achievement and timing of FDA approval of Endosense’s TactiCath irrigated ablation catheter for treatment of paroxysmal atrial fibrillation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?